First Dallas Securities’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$452K Sell
11,920
-9,047
-43% -$417K 0.15% 93
2026
Q2
$1.01M Buy
+20,967
New +$901K 0.33% 68
2025
Q1
– Sell
-5,654
Closed -$486K – 118
2024
Q4
$486K Buy
5,654
+838
+17% +$90.6K 0.2% 85
2024
Q3
$573K Sell
4,816
-4,499
-48% -$600K 0.24% 75
2024
Q2
$1.33M Sell
9,315
-6,161
-40% -$816K 0.58% 43
2024
Q1
$1.99M Sell
15,476
-600
-4% -$71.4K 0.91% 34
2023
Q4
$1.66M Sell
16,076
-4,786
-23% -$473K 0.86% 36
2023
Q3
$2.63M Buy
20,862
+3,648
+21% +$321K 0.6% 52
2023
Q2
$1.39M Buy
17,214
+5,992
+53% +$489K 0.78% 40
2023
Q1
$893K Buy
11,222
+5,200
+86% +$369K 0.53% 49
2022
Q4
$408K Buy
+6,022
New +$353K 0.25% 89

Other funds holding NVO

First Dallas Securities's NVO Position: Q3 2026 in Review

First Dallas Securities reduced its Novo Nordisk (NVO) stake by 43% in Q3 2026, selling an estimated $417K and leaving 11,920 shares worth $452K. The position accounts for 0.15% of the portfolio, ranked #93.

First Dallas Securities first reported a position in NVO in Q4 2022 and has held it in 11 quarters since. The position peaked at $2.63M in Q3 2023. 1,237 funds tracked by Wall St. Rank hold NVO as of Q3 2026.

  • First Dallas Securities held 11,920 shares of Novo Nordisk worth $452K as of Q3 2026.
  • First Dallas Securities sold 9,047 Novo Nordisk shares in Q3 2026, an estimated $417K.
  • Novo Nordisk made up 0.15% of First Dallas Securities's portfolio in Q3 2026, its #93 holding.
  • First Dallas Securities first reported a position in Novo Nordisk in Q4 2022 and has held it in 11 quarters since.
  • First Dallas Securities's Novo Nordisk position peaked at $2.63M in Q3 2023.
  • 1,237 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2026.

Based on First Dallas Securities's 13F filing for Q3 2026, filed 13 Nov 2026.